First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70000 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Andrea Kuemmerle und 13 weiteren Autor:innen. Beteiligte Einrichtung: MMV Medicines for Malaria Venture, Geneva, Switzerland. Hauptthemen laut MEDLINE: Antimalarials, Food-Drug Interactions. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MMV Medicines for Malaria Venture, GSK, Medicines for Malaria Venture.
Abstract (Originalsprache)
Aim
To evaluate the safety, tolerability and pharmacokinetics in healthy participants of orally administered MMV367 (GSK3772701), a novel antimalarial interfering with Plasmodium falciparum acyl coenzyme A synthetase 10/11 function.
Methods
This first‐in‐human study enrolled 47 healthy male and female participants. Part 1 was a randomised, double‐blind, placebo‐controlled study in which four sequential fasted cohorts received MMV367 single ascending doses (100, 300, 750 and 1500 mg) or placebo (six active, two placebo per cohort). Part 2 was a randomised, open‐label crossover (fed‐fasted) pilot food‐effect study of MMV367 440 mg (n = 8). In Part 3 MMV367 400 mg was administered once daily for 3 days in a single cohort (six active, two placebo).
Results
Treatment‐emergent adverse events (TEAEs) occurred in 36.8% (14/38) of participants receiving MMV367 vs 44.4% (4/9) with placebo. There were two MMV367‐related TEAEs, and no serious or severe TEAEs or clinically relevant changes in electrocardiograms, vital signs or laboratory tests. In Part 1 (fasted), maximum plasma concentrations occurred between 2.0 and 5.0 h post dose, with a geometric mean half‐life of 16.5‐18.4 h. Approximate dose proportionality was demonstrated across the dose range (100‐1500 mg). In Part 2, MMV367 relative bioavailability (fed vs fasted) was 161.4% (90% confidence interval 148.3, 175.6) for maximum observed concentration ( C max ), 130.4% (122.2, 139.1) for the area under the curve (AUC) until the last measurable concentration and 132.9% (124.1, 142.3) for AUC extrapolated to infinity. In Part 3, geometric mean day 1:3 exposure ratios (geometric co‐efficient of variability) were 1.9 (4.9%) for C max and 2.1 (7.7%) for the AUC for the defined interval between doses after once‐daily dosing for 3 days.
Conclusions
MMV367 demonstrated acceptable safety, tolerability and pharmacokinetic profiles supporting further development as an antimalarial drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MMV Medicines for Malaria Venture, Geneva, Switzerland.
- Quotient Sciences, Nottingham, UK.
- Mangareva SRL, Kraainem, Belgium.
- AKJ Consulting, Divonne, France.
- GSK, Clinical Pharmacology and Simulation, R&D, Stevenage, UK.
- GSK, Global Health Medicines, R&D, Stevenage, UK.
ORCID-Profile: Andrea Kuemmerle, Nand Singh, Denis Gossen, Annick Janin, Raman Sharma, Anthony Cahn, Rachel A Gibson, Somasekhara R Menakuru, Erin Lambourne, Tom Dove, Francisco-Javier Gamo, Laura Sanz, Benoit Bestgen, Stephan Chalon
Förderung
- MMV Medicines for Malaria Venture
- GSK
- Medicines for Malaria Venture
- Bill & Melinda Gates Foundation
- Bill and Melinda Gates Foundation
Zitieren
APA
Kuemmerle, A., Singh, N., Gossen, D., Janin, A., Sharma, R., Cahn, A., Gibson, R. A., Menakuru, S. R., Lambourne, E., Dove, T., Gamo, F. J., Sanz, L., Bestgen, B., & Chalon, S. (2025). First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70000
Vancouver
Kuemmerle A, Singh N, Gossen D, Janin A, Sharma R, Cahn A, et al. First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70000
BibTeX
@article{Kuemmerle2025,
author = {Kuemmerle, Andrea and Singh, Nand and Gossen, Denis and Janin, Annick and Sharma, Raman and Cahn, Anthony and Gibson, Rachel A and Menakuru, Somasekhara R and Lambourne, Erin and Dove, Tom and Gamo, Francisco-Javier and Sanz, Laura and Bestgen, Benoit and Chalon, Stephan},
title = {First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70000}
}
EUVIMED